

Alison P Galvani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3381828/publications.pdf>

Version: 2024-02-01

156
papers

8,561
citations

61984

43
h-index

64796

79
g-index

170
all docs

170
docs citations

170
times ranked

12935
citing authors

#	ARTICLE	IF	CITATIONS
1	Lives saved and hospitalizations averted by COVID-19 vaccination in New York City: a modeling study. <i>The Lancet Regional Health Americas</i> , 2022, 5, 100085.	2.6	30
2	COVID-19 hospitalizations and deaths averted under an accelerated vaccination program in northeastern and southern regions of the USA. <i>The Lancet Regional Health Americas</i> , 2022, 6, 100147.	2.6	16
3	Estimating COVID-19 Infections, Hospitalizations, and Deaths Following the US Vaccination Campaigns During the Pandemic. <i>JAMA Network Open</i> , 2022, 5, e2142725.	5.9	38
4	Quarantine and testing strategies to ameliorate transmission due to travel during the COVID-19 pandemic: a modelling study. <i>Lancet Regional Health - Europe</i> , The, 2022, 14, 100304.	5.6	20
5	Cost-effective proactive testing strategies during COVID-19 mass vaccination: A modelling study. <i>The Lancet Regional Health Americas</i> , 2022, 8, 100182.	2.6	10
6	Incentives for COVID-19 vaccination. <i>The Lancet Regional Health Americas</i> , 2022, 8, 100205.	2.6	17
7	Exacerbation of COVID-19 mortality by the fragmented United States healthcare system: A retrospective observational study. <i>The Lancet Regional Health Americas</i> , 2022, 12, 100264.	2.6	7
8	Universal healthcare as pandemic preparedness: The lives and costs that could have been saved during the COVID-19 pandemic. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	22
9	Comparative analyses of eighteen rapid antigen tests and RT-PCR for COVID-19 quarantine and surveillance-based isolation. <i>Communications Medicine</i> , 2022, 2, .	4.2	13
10	The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	47
11	Large numbers cause magnitude neglect: The case of government expenditures. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	3
12	Buyer beware: inflated claims of sensitivity for rapid COVID-19 tests. <i>Lancet</i> , The, 2021, 397, 24-25.	13.7	34
13	Cross-country evidence on the association between contact tracing and COVID-19 case fatality rates. <i>Scientific Reports</i> , 2021, 11, 2145.	3.3	31
14	The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. <i>Clinical Infectious Diseases</i> , 2021, 73, 2257-2264.	5.8	376
15	Optimal COVID-19 quarantine and testing strategies. <i>Nature Communications</i> , 2021, 12, 356.	12.8	164
16	Optimizing age-specific vaccination. <i>Science</i> , 2021, 371, 890-891.	12.6	38
17	Universal health care needed to end HIV epidemic in the USA. <i>Lancet HIV</i> , the, 2021, 8, e63-e64.	4.7	1
18	Network structure and rapid HIV transmission among people who inject drugs: A simulation-based analysis. <i>Epidemics</i> , 2021, 34, 100426.	3.0	3

#	ARTICLE	IF	CITATIONS
19	Racial disparities in COVID-19 mortality across Michigan, United States. <i>EClinicalMedicine</i> , 2021, 33, 100761.	7.1	26
20	Comparative cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study. <i>Lancet Public Health</i> , The, 2021, 6, e184-e191.	10.0	106
21	Simulated Identification of Silent COVID-19 Infections Among Children and Estimated Future Infection Rates With Vaccination. <i>JAMA Network Open</i> , 2021, 4, e217097.	5.9	22
22	Evaluation of COVID-19 vaccination strategies with a delayed second dose. <i>PLoS Biology</i> , 2021, 19, e3001211.	5.6	111
23	Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants. <i>EClinicalMedicine</i> , 2021, 35, 100865.	7.1	100
24	Mechanistic basis of post-treatment control of SIV after anti-Î±4Î²7 antibody therapy. <i>PLoS Computational Biology</i> , 2021, 17, e1009031.	3.2	4
25	Lessons learned during COVID-19: Building critical care/ICU capacity for resource limited countries with complex emergencies in the World Health Organization Eastern Mediterranean Region. <i>Journal of Global Health</i> , 2021, 11, 03083.	2.7	15
26	Multifaceted strategies for the control of COVID-19 outbreaks in long-term care facilities in Ontario, Canada. <i>Preventive Medicine</i> , 2021, 148, 106564.	3.4	40
27	Can the USA return to pre-COVID-19 normal by July 4?. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1073-1074.	9.1	12
28	The interplay between COVID-19 restrictions and vaccination. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1053-1054.	9.1	8
29	Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions. <i>Vaccine</i> , 2021, 39, 5037-5045.	3.8	17
30	Influenza vaccination should have no border: cost-effectiveness of cross-border subsidy. <i>BMC Public Health</i> , 2021, 21, 1543.	2.9	3
31	Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	345
32	The Unrecognized Death Toll of COVID-19 in the United States. <i>The Lancet Regional Health Americas</i> , 2021, 1, 100033.	2.6	9
33	Population Immunity Against COVID-19 in the United States. <i>Annals of Internal Medicine</i> , 2021, 174, 1586-1591.	3.9	20
34	Uncoupling vaccination from politics: a call to action. <i>Lancet</i> , The, 2021, 398, 1211-1212.	18.7	53
35	Routine saliva testing for the identification of silent coronavirus disease 2019 (COVID-19) in healthcare workers. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 1189-1193.	1.8	20
36	Importance of non-pharmaceutical interventions in the COVID-19 vaccination era: A case study of the Seychelles. <i>Journal of Global Health</i> , 2021, 11, 03104.	2.7	11

#	ARTICLE	IF	CITATIONS
37	Implications of suboptimal COVID-19 vaccination coverage in Florida and Texas. <i>Lancet Infectious Diseases, The</i> , 2021, 21, 1493-1494.	9.1	16
38	The durability of immunity against reinfection by SARS-CoV-2: a comparative evolutionary study. <i>Lancet Microbe, The</i> , 2021, 2, e666-e675.	7.3	147
39	Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA. <i>Lancet, The</i> , 2021, 398, 2186-2192.	13.7	106
40	Implementation of Syringe Services Programs to Prevent Rapid Human Immunodeficiency Virus Transmission in Rural Counties in the United States: A Modeling Study. <i>Clinical Infectious Diseases</i> , 2020, 70, 1096-1102.	5.8	27
41	Spatio-temporal dynamics of measles outbreaks in Cameroon. <i>Annals of Epidemiology</i> , 2020, 42, 64-72.e3.	1.9	8
42	Impact of Social Distancing Measures on Coronavirus Disease Healthcare Demand, Central Texas, USA. <i>Emerging Infectious Diseases</i> , 2020, 26, 2361-2369.	4.3	93
43	The impact of mask-wearing and shelter-in-place on COVID-19 outbreaks in the United States. <i>International Journal of Infectious Diseases</i> , 2020, 101, 334-341.	3.3	48
44	The burden of childhood pneumonia in India and prospects for control. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 643-645.	5.6	7
45	The imperative for universal healthcare to curtail the COVID-19 outbreak in the USA. <i>EClinicalMedicine</i> , 2020, 23, 100380.	7.1	15
46	Prosocial polio vaccination in Israel. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 13138-13144.	7.1	16
47	The effect of Medicare for All on rural hospitals – Authors' reply. <i>Lancet, The</i> , 2020, 396, 1392-1393.	13.7	1
48	The case for replacing live oral polio vaccine with inactivated vaccine in the Americas. <i>Lancet, The</i> , 2020, 395, 1163-1166.	13.7	17
49	Modeling mitigation of influenza epidemics by baloxavir. <i>Nature Communications</i> , 2020, 11, 2750.	12.8	36
50	Cost-effectiveness of transitional US plans for universal health care. <i>Lancet, The</i> , 2020, 395, 1692-1693.	13.7	3
51	Temporal estimates of case-fatality rate for COVID-19 outbreaks in Canada and the United States. <i>Cmaj</i> , 2020, 192, E666-E670.	2.0	65
52	COVID-19 on the African continent. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 1368-1370.	9.1	25
53	The implications of silent transmission for the control of COVID-19 outbreaks. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 17513-17515.	7.1	419
54	Curbing the 2019 Samoa measles outbreak. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 287-288.	9.1	4

#	ARTICLE	IF	CITATIONS
55	Improving the prognosis of health care in the USA. <i>Lancet, The</i> , 2020, 395, 524-533.	13.7	63
56	Assessing the impact of aggregating disease stage data in model predictions of human African trypanosomiasis transmission and control activities in Bandundu province (DRC). <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0007976.	3.0	23
57	Projecting the demand for ventilators at the peak of the COVID-19 outbreak in the USA. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 1123-1125.	9.1	53
58	Impact of international travel and border control measures on the global spread of the novel 2019 coronavirus outbreak. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 7504-7509.	7.1	429
59	Projecting hospital utilization during the COVID-19 outbreaks in the United States. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 9122-9126.	7.1	441
60	Projecting demand for critical care beds during COVID-19 outbreaks in Canada. <i>Cmaj</i> , 2020, 192, E489-E496.	2.0	132
61	Evaluation of the Cherokee Nation Hepatitis C Virus Elimination Program in the First 22 Months of Implementation. <i>JAMA Network Open</i> , 2020, 3, e2030427.	5.9	15
62	Quantifying risk factors to guide progress towards leprosy elimination. <i>The Lancet Global Health</i> , 2019, 7, e1154-e1155.	6.3	2
63	The global burden of HIV and prospects for control. <i>Lancet HIV,the</i> , 2019, 6, e809-e811.	4.7	81
64	Modelling microbial infection to address global health challenges. <i>Nature Microbiology</i> , 2019, 4, 1612-1619.	13.3	34
65	Impact of One-Health framework on vaccination cost-effectiveness: A case study of rabies in Ethiopia. <i>One Health</i> , 2019, 8, 100103.	3.4	7
66	Resolving the apparent transmission paradox of African sleeping sickness. <i>PLoS Biology</i> , 2019, 17, e3000105.	5.6	47
67	Metrics and benchmarks for HIV transition – Authors' reply. <i>Lancet HIV,the</i> , 2019, 6, e150.	4.7	0
68	Ebola vaccination in the Democratic Republic of the Congo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10178-10183.	7.1	38
69	The exacerbation of Ebola outbreaks by conflict in the Democratic Republic of the Congo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 24366-24372.	7.1	72
70	Future epidemiological and economic impacts of universal influenza vaccines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 20786-20792.	7.1	26
71	The impact of vector migration on the effectiveness of strategies to control gambiense human African trypanosomiasis. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007903.	3.0	7
72	What Is the Value of Different Zika Vaccination Strategies to Prevent and Mitigate Zika Outbreaks?. <i>Journal of Infectious Diseases</i> , 2019, 220, 920-931.	4.0	8

#	ARTICLE	IF	CITATIONS
73	Harnessing synergies at the interface of public health and the security sector. <i>Lancet, The</i> , 2019, 393, 207-209.	13.7	12
74	Underestimation of the global burden of schistosomiasis. <i>Lancet, The</i> , 2018, 391, 307-308.	13.7	37
75	Optimizing the impact of low-efficacy influenza vaccines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 5151-5156.	7.1	48
76	Dynamic Models of Infectious Disease Transmission in Prisons and the General Population. <i>Epidemiologic Reviews</i> , 2018, 40, 40-57.	3.5	57
77	The economic value of identifying and treating Chagas disease patients earlier and the impact on <i>Trypanosoma cruzi</i> transmission. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006809.	3.0	32
78	Defining control of HIV epidemics. <i>Lancet HIV,the</i> , 2018, 5, e667-e670.	4.7	44
79	Policy Lessons From Quantitative Modeling of Leprosy. <i>Clinical Infectious Diseases</i> , 2018, 66, S281-S285.	5.8	14
80	Assessing Strategies Against Gambiense Sleeping Sickness Through Mathematical Modeling. <i>Clinical Infectious Diseases</i> , 2018, 66, S286-S292.	5.8	37
81	The Challenge of Vanquishing HIV for the Next Generation—Facing the Future. <i>JAMA Pediatrics</i> , 2018, 172, 609.	6.2	1
82	Evaluating Vaccination Strategies for Zika Virus in the Americas. <i>Annals of Internal Medicine</i> , 2018, 168, 621-630.	3.9	11
83	Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study. <i>Lancet HIV,the</i> , 2018, 5, e498-e505.	4.7	37
84	Are the London Declaration's 2020 goals sufficient to control Chagas disease?: Modeling scenarios for the Yucatan Peninsula. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006337.	3.0	16
85	Global elimination of lymphatic filariasis. <i>Lancet Infectious Diseases, The</i> , 2017, 17, 358-359.	9.1	17
86	Comparison and validation of two computational models of Chagas disease: A thirty year perspective from Venezuela. <i>Epidemics</i> , 2017, 18, 81-91.	3.0	14
87	Forecasting the new case detection rate of leprosy in four states of Brazil: A comparison of modelling approaches. <i>Epidemics</i> , 2017, 18, 92-100.	3.0	15
88	Characterizing risk of Ebola transmission based on frequency and type of case's contact exposures. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160301.	4.0	18
89	Assessing real-time Zika risk in the United States. <i>BMC Infectious Diseases</i> , 2017, 17, 284.	2.9	41
90	Strategies for <i>Trypanosoma brucei gambiense</i> elimination. <i>The Lancet Global Health</i> , 2017, 5, e10-e11.	6.3	6

#	ARTICLE	IF	CITATIONS
91	Modelling the impact of antimalarial quality on the transmission of sulfadoxine-pyrimethamine resistance in Plasmodium falciparum. Infectious Disease Modelling, 2017, 2, 161-187.	1.9	4
92	Fund global health: Save lives and money. Science, 2017, 356, 1018-1019.	12.6	1
93	Effectiveness of UNAIDS targets and HIV vaccination across 127 countries. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 4017-4022.	7.1	62
94	California Universal Health Care Bill: an economic stimulus and life-saving proposal. Lancet, The, 2017, 390, 2012-2014.	13.7	1
95	Saving lives efficiently across sectors: the need for a Congressional cost-effectiveness committee. Lancet, The, 2017, 390, 2410-2412.	13.7	8
96	The potential economic burden of Zika in the continental United States. PLoS Neglected Tropical Diseases, 2017, 11, e0005531.	3.0	49
97	Quantitative assessment of the impact of partially protective anti-schistosomiasis vaccines. PLoS Neglected Tropical Diseases, 2017, 11, e0005544.	3.0	29
98	Quantifying Transmission of <i>Clostridium difficile</i> within and outside Healthcare Settings. Emerging Infectious Diseases, 2016, 22, 608-616.	4.3	48
99	Determinants of Human African Trypanosomiasis Elimination via Paratransgenesis. PLoS Neglected Tropical Diseases, 2016, 10, e0004465.	3.0	21
100	A Cost-Effectiveness Tool for Informing Policies on Zika Virus Control. PLoS Neglected Tropical Diseases, 2016, 10, e0004743.	3.0	56
101	Using Community-Level Prevalence of Loa loa Infection to Predict the Proportion of Highly-Infected Individuals: Statistical Modelling to Support Lymphatic Filariasis and Onchocerciasis Elimination Programs. PLoS Neglected Tropical Diseases, 2016, 10, e0005157.	3.0	15
102	Stimulating Influenza Vaccination via Prosocial Motives. PLoS ONE, 2016, 11, e0159780.	2.5	53
103	Evaluating the effectiveness of localized control strategies to curtail chikungunya. Scientific Reports, 2016, 6, 23997.	3.3	20
104	Interrupting Ebola Transmission in Liberia Through Community-Based Initiatives. Annals of Internal Medicine, 2016, 164, 367.	3.9	42
105	Human-environment interactions in population and ecosystem health. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14502-14506.	7.1	83
106	One Health approach to cost-effective rabies control in India. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 14574-14581.	7.1	63
107	Philippine drug war and impending public health crisis. Lancet, The, 2016, 388, 2870.	13.7	9
108	Epidemiological and Economic Effects of Priming With the Whole-Cell <i>Bordetella pertussis</i> Vaccine. JAMA Pediatrics, 2016, 170, 459.	6.2	22

#	ARTICLE	IF	CITATIONS
109	Cost-effectiveness of next-generation vaccines: The case of pertussis. <i>Vaccine</i> , 2016, 34, 3405-3411.	3.8	3
110	Retrospective Analysis of the 2014-2015 Ebola Epidemic in Liberia. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 833-839.	1.4	10
111	National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 5107-5112.	7.1	46
112	Cost-Effectiveness of Rotavirus Vaccination in France- Accounting for Indirect Protection. <i>Value in Health</i> , 2016, 19, 811-819.	0.3	8
113	Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. <i>Lancet</i> , 2016, 388, 1089-1102.	13.7	458
114	Pregnancy outcomes in Liberian women who conceived after recovery from Ebola virus disease. <i>The Lancet Global Health</i> , 2016, 4, e678-e679.	6.3	30
115	Optimal frequency of rabies vaccination campaigns in Sub-Saharan Africa. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2016, 283, 20161211.	2.6	10
116	Vaccination strategies against respiratory syncytial virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 13239-13244.	7.1	70
117	Social contacts, vaccination decisions and influenza in Japan. <i>Journal of Epidemiology and Community Health</i> , 2016, 70, 162-167.	3.7	77
118	Optimizing age of cytomegalovirus screening and vaccination to avert congenital disease in the US. <i>Vaccine</i> , 2016, 34, 225-229.	3.8	9
119	Respiratory virus transmission dynamics determine timing of asthma exacerbation peaks: Evidence from a population-level model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 2194-2199.	7.1	46
120	Cross-Cultural Household Influence on Vaccination Decisions. <i>Medical Decision Making</i> , 2016, 36, 844-853.	2.4	13
121	Disease Surveillance on Complex Social Networks. <i>PLoS Computational Biology</i> , 2016, 12, e1004928.	3.2	46
122	Next Steps for Ebola Vaccination: Deployment in Non-Epidemic, High-Risk Settings. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004802.	3.0	8
123	Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. <i>PLoS ONE</i> , 2016, 11, e0165614.	2.5	20
124	Public health impact of disease-behavior dynamics. <i>Physics of Life Reviews</i> , 2015, 15, 55-56.	2.8	2
125	Evaluating long-term effectiveness of sleeping sickness control measures in Guinea. <i>Parasites and Vectors</i> , 2015, 8, 550.	2.5	41
126	Spatial heterogeneity in projected leprosy trends in India. <i>Parasites and Vectors</i> , 2015, 8, 542.	2.5	23

#	ARTICLE	IF	CITATIONS
127	Modelling control of <i>Schistosoma haematobium</i> infection: predictions of the long-term impact of mass drug administration in Africa. <i>Parasites and Vectors</i> , 2015, 8, 529.	2.5	50
128	Under-reporting and case fatality estimates for emerging epidemics. <i>BMJ</i> , The, 2015, 350, h1115-h1115.	6.0	38
129	Integrating Community-Based Interventions to Reverse the Convergent TB/HIV Epidemics in Rural South Africa. <i>PLoS ONE</i> , 2015, 10, e0126267.	2.5	21
130	Spatial and Temporal Clustering of Chikungunya Virus Transmission in Dominica. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003977.	3.0	27
131	Harnessing Case Isolation and Ring Vaccination to Control Ebola. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003794.	3.0	31
132	Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 703-710.	9.1	64
133	Efficacy and Optimization of Palivizumab Injection Regimens Against Respiratory Syncytial Virus Infection. <i>JAMA Pediatrics</i> , 2015, 169, 341.	6.2	39
134	Strategies to prevent future Ebola epidemics. <i>Lancet</i> , The, 2015, 386, 131.	13.7	11
135	Reassessment of HIV-1 Acute Phase Infectivity: Accounting for Heterogeneity and Study Design with Simulated Cohorts. <i>PLoS Medicine</i> , 2015, 12, e1001801.	8.4	75
136	Comparing the Impact of Artemisinin-Based Combination Therapies on Malaria Transmission in Sub-Saharan Africa. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 555-560.	1.4	13
137	Impact of bed capacity on spatiotemporal shifts in Ebola transmission. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14125-14126.	7.1	6
138	Effect of Ebola Progression on Transmission and Control in Liberia. <i>Annals of Internal Medicine</i> , 2015, 162, 11-17.	3.9	83
139	Nine challenges in incorporating the dynamics of behaviour in infectious diseases models. <i>Epidemics</i> , 2015, 10, 21-25.	3.0	174
140	Disease elimination and re-emergence in differential-equation models. <i>Journal of Theoretical Biology</i> , 2015, 387, 174-180.	1.7	12
141	Epidemiological and Viral Genomic Sequence Analysis of the 2014 Ebola Outbreak Reveals Clustered Transmission. <i>Clinical Infectious Diseases</i> , 2015, 60, 1079-1082.	5.8	59
142	Ethical Alternatives to Experiments with Novel Potential Pandemic Pathogens. <i>PLoS Medicine</i> , 2014, 11, e1001646.	8.4	106
143	Impact of <i>Schistosoma mansoni</i> on Malaria Transmission in Sub-Saharan Africa. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3234.	3.0	25
144	Cellular Superspreaders: An Epidemiological Perspective on HIV Infection inside the Body. <i>PLoS Pathogens</i> , 2014, 10, e1004092.	4.7	20

#	ARTICLE	IF	CITATIONS
145	An Innovative Influenza Vaccination Policy: Targeting Last Season's Patients. <i>PLoS Computational Biology</i> , 2014, 10, e1003643.	3.2	15
146	Strategies for containing Ebola in West Africa. <i>Science</i> , 2014, 346, 991-995.	12.6	244
147	Dynamics and control of Ebola virus transmission in Montserrado, Liberia: a mathematical modelling analysis. <i>Lancet Infectious Diseases</i> , The, 2014, 14, 1189-1195.	9.1	154
148	Cost-effectiveness of influenza vaccination in prior pneumonia patients in Israel. <i>Vaccine</i> , 2014, 32, 4198-4205.	3.8	15
149	Evaluating the potential impact of mass praziquantel administration for HIV prevention in <i>Schistosoma haematobium</i> high-risk communities. <i>Epidemics</i> , 2014, 7, 22-27.	3.0	21
150	Probabilistic uncertainty analysis of epidemiological modeling to guide public health intervention policy. <i>Epidemics</i> , 2014, 6, 37-45.	3.0	29
151	Cost-Effectiveness of Canine Vaccination to Prevent Human Rabies in Rural Tanzania. <i>Annals of Internal Medicine</i> , 2014, 160, 91-100.	3.9	71
152	Cost-effectiveness of a community-based intervention for reducing the transmission of <i>Schistosoma haematobium</i> and HIV in Africa. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 7952-7957.	7.1	35
153	HIV and <i>Schistosoma haematobium</i> prevalences correlate in sub-Saharan Africa. <i>Tropical Medicine and International Health</i> , 2013, 18, 1174-1179.	2.3	41
154	Social Factors in Epidemiology. <i>Science</i> , 2013, 342, 47-49.	12.6	188
155	Direct and Indirect Effects of Rotavirus Vaccination: Comparing Predictions from Transmission Dynamic Models. <i>PLoS ONE</i> , 2012, 7, e42320.	2.5	60
156	Optimizing Influenza Vaccine Distribution. <i>Science</i> , 2009, 325, 1705-1708.	12.6	370